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Mycobacterium bovis BCG is administered to human neonates in many countries worldwide. The objective of
the study was to assess if BCG could act as an adjuvant for polysaccharide-protein conjugate vaccines in
newborns and thereby induce protective immunity against encapsulated bacteria in early infancy when sus-
ceptibility is high. We assessed whether BCG could enhance immune responses to a meningococcal C (MenC)
conjugate vaccine, MenC-CRM197, in mice primed as neonates, broaden the antibody response from a domi-
nant IgG1 toward a mixed IgG1 and IgG2a/IgG2b response, and increase protective efficacy, as measured by
serum bactericidal activity (SBA). Two-week-old mice were primed subcutaneously (s.c.) with MenC-CRM197.
BCG was administered concomitantly, a day or a week before MenC-CRM197. An adjuvant effect of BCG was
observed only when it was given concomitantly with MenC-CRM197, with increased IgG response (P  0.002)
and SBA (8-fold) after a second immunization with MenC-CRM197 without BCG, indicating increased T-cell
help. In neonatal mice (1 week old) primed s.c. with MenC-CRM197 together with BCG, MenC-polysaccharide
(PS)-specific IgG was enhanced compared to MenC-CRM197 alone (P  0.0015). Sixteen days after the second
immunization with MenC-CRM197, increased IgG (P < 0.05), IgG1 (P < 0.05), IgG2a (P  0.06), and IgG2b
(P< 0.05) were observed, and only mice primed with MenC-CRM197 plus BCG showed affinity maturation and
detectable SBA (SBA > 128). Thus, vaccination with a meningococcal conjugate vaccine (and possibly with
other conjugates) may benefit from concomitant administration of BCG in the neonatal period to accelerate
and enhance production of protective antibodies, compared to the current infant administration of conjugate
which follows BCG vaccination at birth.
Neisseria meningitis remains a worldwide threat and annually
causes 1.2 million cases of meningococcal disease, claiming
135,000 lives (63). Although significant advances have been
made in the development and coverage of vaccines, the disease
burden remains high, highest in the meningitis belt in sub-
Saharan Africa, where epidemics occur in waves lasting 3 to 4
years, the last in 2009 (64). Due to the immaturity of the
immune system and decline of maternal antibodies (Abs), the
incidence of meningococcal disease peaks in the first year of
life, although it varies between countries due to differences in
serogroup distributions (21, 30), and mortality is highest in
infancy and for teenagers (50). Thus, it is of utmost importance
to design early-life vaccination strategies that induce protective
immunity in early infancy as well as long-lasting immunological
memory against these major pathogens.
Meningococcal polysaccharide (PS) vaccines have been
available since the 1960s (42). However, polysaccharides are
T-cell-independent antigens, are poorly immunogenic in chil-
dren under 2 years of age (54), and may induce hyporespon-
siveness (11, 15, 32, 34).
In the 1980s conjugate vaccines were developed, in which
the PS is conjugated to a protein carrier (46). Conjugate vac-
cines are T-cell dependent (TD) (53), and unlike PS vaccines
they are immunogenic in young infants, induce immunological
memory (45), reduce carriage (11, 60), and offer long-term
protection (33, 34).
Similar to most protein vaccines (reviewed in reference 51),
immune responses to conjugate vaccines are age dependent in
both mice (4, 25) and humans (9). Meningococcal serogroup C
(MenC) conjugate vaccines are immunogenic in infants and
have successfully been introduced into many countries world-
wide (55). Two quadrivalent meningococcal conjugate vaccines
(serogroups A, C, W-135, and Y) are licensed. In clinical trials,
their immunogenicity was considered modest (MenACWY-D)
(44) or sufficient (52) in infants, the age group most vulnerable
to meningococcal disease. However, their use is recommended
in the United States for vaccination of all adolescents 11 to 18
years of age and for those aged 2 to 55 years who are at
increased risk of meningococcal disease (41). In April 2011
Menectra was approved for use in infants over the age of 9
months but is not yet recommended by the CDC. Hence,
well-tolerated effective adjuvants may enhance and accelerate
immune responses to conjugate vaccines in neonates and in-
fants (24, 25, 38), the age group most vulnerable to meningo-
coccal disease. Mycobacterium bovis bacillus Calmette-Gue´rin
(BCG) is administered to human neonates in many countries
worldwide. It is by far the most widely used vaccine worldwide,
and since it was first introduced in 1921, more than 3 billion
doses have been delivered (1). BCG is efficacious against tu-
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berculosis (TB) in infants and young children, but protection
against adolescent and adult tuberculosis, the most prevalent
form of the disease, is insufficient (6, 28). Newborns immu-
nized with BCG show increased Th1-type responses, with sim-
ilar gamma interferon (IFN-) production by CD4 T cells, as
when BCG is given later in life (35, 61). BCG has also been
shown to increase B- and T-cell responses to unrelated anti-
gens in early life (39).
Maturation and responses of the immune system of 1- and
3-week-old mice correspond to those of human neonates and
infants, respectively (31, 51). We have previously reported on
age-dependent antibody production, B-cell, T-cell, and den-
dritic cell activation, and immunological memory elicited by
pneumococcal conjugate vaccines in neonatal and infant mice
(4, 20, 24, 25). If BCG has adjuvant effects on neonatal re-
sponses to meningococcal conjugate vaccines, it would be ben-
eficial to administer these vaccines combined to neonates in
areas where both Mycobacterium tuberculosis and Neisseria
meningitidis are endemic and disease burden is high.
We investigated the ability of BCG to act as an adjuvant and
enhance the antibody responses to the monovalent MenC-
CRM197 in mice primed as neonates, as well as its effect on
antibody, affinity, and protective efficacy, measured as serum
bactericidal activity (SBA). We also assessed the ability of
BCG to direct the immune responses from a dominant Th2-
associated IgG1 that is characteristic for neonatal responses
toward a mixed response of IgG1 versus IgG2a and IgG2b
(Th2 versus Th1 associated). In mice IgG2a and IgG2b are
potent activators of complement and confer protection against
encapsulated pathogens (58). Since meningococci do not infect
mice, the effect of BCG on the protective efficacy of MenC-
CRM197 could not be studied in vivo. Therefore, SBA was
measured and a titer of 128 used as a correlate of protection
(5). Two-week-old mice were primed subcutaneously (s.c.)
with MenC-CRM197. BCG was administered concomitantly, 1
day or 1 week before MenC-CRM197 priming. The results show
that BCG functions only as an adjuvant if given concomitantly
with the MenC-CRM197 conjugate. In the next set of experi-
ments, mice were primed as neonates (1 week old) with MenC-
CRM197 with or without concomitant administration of BCG.
MATERIALS AND METHODS
Animals. Adult NMRI mice were purchased from M&B AS (Ry, Denmark)
and kept in microisolator cages with free access to commercial food pellets and
water. They were housed under standardized conditions at the Institute of Ex-
perimental Pathology at Keldur (Reykjavik, Iceland) with regulated daylight,
humidity, and temperature. Breeding cages were checked daily for new births,
and the pups kept with their mothers until weaning at the age of 4 weeks. The
study was authorized by the Animal Experimental Committee of Iceland.
Vaccines and adjuvants. The monovalent meningococcal polysaccharide C
conjugated to CRM197 (MenC-CRM197), a nontoxic variant of diphtheria toxoid
produced by site-directed mutagenesis (10), was provided by Novartis Vaccines
& Diagnostics (Siena, Italy). BCG was purchased from Statens Serum Institut
(Copenhagen, Denmark).
Immunizations. For the initial set of experiments, 2-week-old mice, 8 per
group, were immunized s.c. with 2.5 g MenC-CRM197. BCG (1 to 2 105 CFU)
was administered concomitantly, 1 day before or 1 week before MenC-CRM197
immunization. Sixteen days later a second dose of MenC-CRM197 without BCG
was administered s.c. For a second set of experiments, neonatal (1-week-old)
mice, 8 per group, were immunized with 2.5 g MenC-CRM197 s.c., and BCG (2
to 8  105 CFU) was given concomitantly. A 50-l vaccine solution was injected
in the scapular girdle. Sixteen days later the mice received a second s.c. dose of
MenC-CRM197 (2.5 l). Age-matched mice that received saline were used as
controls. In a third set of experiments, mice primed as neonates with MenC-
CRM197 with or without BCG received a second and third MenC-CRM197
immunization 16 and 28 days after priming. Mice were bled from the tail vein at
3 weeks of age (not possible to obtain samples earlier) and weekly until 6 weeks
of age. Serum was isolated and stored at 20°C until analyses were performed.
Each set of experiment was performed at least twice, with comparable results.
Antibody measurement. MenC-PS-specific antibodies (IgG, IgG1, IgG2a, and
IgG2b) were measured essentially as previously described (13). Microtiter plates
(MaxiSorp; Nunc, Roskilde, Denmark) were coated with 5.0 g of purified
meningococcal type C capsular PS (Novartis Vaccines and Diagnostics) in phos-
phate-buffered saline (PBS) with methylated human serum albumin (5 g/ml)
(NIBSC, South Mimms, United Kingdom) and incubated overnight at 4°C. The
plates were then blocked with 1% (wt/vol) gelatin (BDH Chemicals Ltd., Poole,
United Kingdom) in PBS (pH 7.2) and incubated for 3 h at 37°C. Following
fixation with 10% (wt/vol) saccharose (Merck, Darmstadt, Germany) and 4%
(wt/vol) polyvinylpyrrolidone (Sigma, St. Louis, MO) for 2 h at room tempera-
ture, the plates were dried and stored at 4°C until use. Serum samples and
standard were serially diluted in PBS-Tween (0.05%) containing 1% bovine
serum albumin (BSA) (Sigma) in duplicate and incubated in MenC-PS-coated
microtiter plates overnight at 4°C. After the plates were washed, horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG, IgG1, IgG2a, or IgG2b
(Southern Biotechnology Associates, Inc., Birmingham, AL) was added and
incubated for 3 h at 37°C. For development of the enzyme reaction, 3,3,5,5-
tetramethylbenzidine peroxidase substrate (Kirkegaard & Perry Laboratories,
Gaithersburg, MD) was incubated for 10 min according to the manufacturer’s
instructions, and the reaction stopped by 0.18 M H2SO4. The absorbance was
measured at 450 nm in an enzyme-linked immunosorbent assay (ELISA) spec-
trophotometer (Titertek Multiscan Plus MK II; ICN Flow Laboratories, Irvine,
United Kingdom).
The results were calculated from standard curves constructed by hyperimmu-
nized reference serum. The titer of the reference corresponded to the inverse of
the dilution, giving an optical density of 1.0. Results are expressed as mean log
ELISA units (EU)/ml  the standard deviation (SD) for each group and time
point.
Avidity. Avidity of MenC-specific IgG was measured by an ELISA as described
above, including a potassium thiocyanate (KSCN) elution step (16). After the
serum incubation step, serial dilutions of KSCN (7.5 to 0.117 M) or PBS-Tween
(100% binding) were added to the wells and incubated for 15 min at room
temperature. The remaining bound Ab was detected with alkaline phosphatase-
conjugated goat anti-mouse IgG (Southern Biotechnology Associates, Inc.). The
reaction was developed with p-nitrophenylphosphate (p-NPP) (Sigma) in dieth-
anolamine buffer (pH 9.8), and absorbance was read at 405 nm.
Results are expressed as follows: avidity index (AI) 	 M KSCN needed to
displace 50% of the bound antibodies.
SBA. Bactericidal antibodies were determined in serum pools from each group
(equal volumes from each mouse) as previously described (3, 36). Briefly, N.
meningitidis strain C11 was grown overnight at 37°C on chocolate agar plates
(starting from a frozen stock) with 5% CO2. Colonies were collected and used to
inoculate 7 ml of Mueller-Hinton broth containing 0.25% glucose to reach an
optical density at 600 nm (OD600) of 0.05 to 0.06. The culture was incubated for
approximately 1.5 h at 37°C with 5% CO2 with shaking until the OD600 reached
0.23 to 0.24. Bacteria were diluted in Gey’s balanced salt solution (Sigma) and
1% (wt/vol) BSA (Sigma) at the working dilution of 105 CFU/ml. The total
volume of the final reaction mixture was 50 l, with 25 l of a serial 2-fold
dilution of test serum, 12.5 l of bacteria at the working dilution, and 12.5 l of
baby rabbit complement. Controls included bacteria incubated with complement
and immune sera incubated with bacteria and complement inactivated by heating
at 56°C for 30 min. Immediately after the addition of the baby rabbit comple-
ment, the controls were plated on Mueller-Hinton agar plates using the tilt
method (time zero). The plates were incubated for 1 h at 37°C with 5% CO2 with
rotation. Each sample was transferred to Mueller-Hinton agar plates as spots,
whereas the controls were transferred to Mueller-Hinton agar plates using the
tilt method (time 1). Agar plates were incubated for 18 h at 37°C with 5% CO2,
and the colonies corresponding to time zero and time 1 were counted. The data
were used to calculate the reciprocal serum dilution at which 50% of the bacteria
are killed. The SBA detection limit is 16 and is indicated with a dotted line in Fig.
2b. Samples with undetectable SBA were arbitrarily assigned an SBA titer of 8,
corresponding to half the detection limit. An SBA titer of 64 is considered
protective (5).
Statistical analysis. The nonparametric Mann-Whitney test was used to com-
pare log antibody titers and the AI between groups and time points. A P value
of 
0.05 was considered statistically significant.
VOL. 18, 2011 EFFECTS OF BCG ON MenC CONJUGATE VACCINATION 1937
RESULTS
The ability of BCG to act as an adjuvant and enhance the
immune responses to MenC-CRM197 in an early-life mouse
model was investigated. In the first set of experiments, 2-week-
old mice were immunized with MenC-CRM197 and the effect
of BCG administration a week before priming and a day before
or at the same time as MenC-CRM197 immunization on im-
mune response was assessed by comparing these mice with
mice that received MenC-CRM197 without BCG. The second
immunization with MenC-CRM197 was administered 16 days
later to allow the germinal center reaction to be completed
(40) and antibody levels to rise. Age-matched control mice
received saline at both time points.
The adjuvant activity of BCG is optimal if given concomi-
tantly with MenC-CRM197. Two-week-old mice that received
BCG (1 to 2  105 CFU) concomitantly with MenC-CRM197
showed significantly higher MenC-PS-specific IgG levels after
the first dose than mice pretreated with BCG 1 day (P
 0.001)
or a week (P 	 0.015) before priming with MenC-CRM197
(Fig. 1a). Only mice primed with MenC-CRM197 and BCG
concomitantly showed significantly higher MenC-PS-specific
IgG levels than mice that received saline.
After the second immunization with MenC-CRM197, mice
primed with MenC-CRM197 and BCG concomitantly showed
the highest MenC-PS-specific IgG levels (Fig. 1a), significantly
higher than mice pretreated with BCG 1 day (P 
 0.001) or 7
days (P 
 0.0015) before MenC-CRM197 priming and higher
than mice that received only MenC-CRM197 (P 	 0.002) or
saline (P
 0.001). The mice pretreated with BCG 1 day before
MenC-CRM197 priming showed MenC-PS-specific IgG levels
that were lower than those of mice that were pretreated with
BCG a week before priming (P	 0.038), but not different from
those of mice that received MenC-CRM197 only. The bacteri-
cidal activity (SBA titer  64) and affinity maturation of
MenC-PS-specific IgG were detected only after the second
MenC-CRM197 immunization in mice that received MenC-
CRM197 and BCG concomitantly for the neonatal priming
(data not shown).
After the second immunization with MenC-CRM197, there
was a shift in the ratio of IgG subclasses of MenC-PS-specific
antibodies in mice primed with MenC-CRM197 plus BCG con-
comitantly (Fig. 1b), from a dominant Th2-associated IgG1 to
a more mixed IgG1, IgG2a, and IgG2b response. The mice that
received MenC-CRM197 plus BCG concomitantly had signifi-
cantly higher IgG2a than mice that received BCG 1 day before
MenC-CRM197 priming (P 	 0.006). IgG2a was undetectable
in mice that received BCG 7 days before MenC-CRM197 and
in mice that received no BCG. MenC-PS-specific IgG1 was
also increased in mice that received MenC-CRM197 plus BCG
concomitantly compared to mice that received BCG 1 day
before MenC-CRM197 (P 	 0.005) or no BCG (P 	 0.015).
Coadministration of BCG has an adjuvant effect on neona-
tal priming with MenC-CRM197. In a second set of experi-
ments we studied further if BCG had an adjuvant effect on
neonatal priming with MenC-CRM197. MenC-CRM197 was ad-
ministered s.c. to 1-week-old mice with or without concomitant
administration of BCG (4 to 8 105 CFU) s.c., and the second
MenC-CRM197 immunization was given 16 days later. Sixteen
days after only one neonatal immunization, the mice primed
with MenC-CRM197 plus BCG showed higher MenC-PS-spe-
cific IgG levels than mice that received MenC-CRM197 (P 	
0.0015) or saline (P 
 0.001) (Fig. 2a), demonstrating, already
in infancy, the beneficial effect of BCG on antibody levels.
Two weeks after the second immunization with MenC-
CRM197, mice initially primed with MenC-CRM197 plus BCG
as neonates showed higher MenC-PS-specific IgG levels than
mice primed with MenC-CRM197 alone (P 
 0.05) and higher
levels than control mice that received saline (P 
 0.001) (Fig.
2a). If an MenC-CRM197 booster was administered 2 weeks
after the second immunization, mice primed as neonates with
MenC-CRM197 plus BCG still showed higher MenC-PS-spe-
cific IgG levels than mice primed with MenC-CRM197 (P 

0.05) (data not shown).
Effects of concomitant administration of BCG on MenC-PS-
specific IgG subclasses, affinity maturation, and protective
efficacy. After the second immunization with MenC-CRM197,
MenC-PS-specific IgG1 levels were higher in mice primed as
neonates with MenC-CRM197 plus BCG than in mice that
received MenC-CRM197 only (P 
 0.05) (Fig. 3a). MenC-PS-
FIG. 1. Antibody response of mice immunized with MenC-CRM197
at 2 weeks of age with or without BCG treatment and receiving a
second immunization with MenC-CRM197. Mice received BCG a week
before (7d), a day before (1d), or at the same time that MenC-
CRM197 was given at 2 weeks of age or did not receive BCG. Sixteen
days later the mice received a second immunization with MenC-
CRM197. Control mice received saline at both times. (a) MenC-PS-
specific IgG levels 2 weeks after priming (light gray columns) and 2
weeks after the second immunization (dark gray columns). The results
are presented as mean  SD for each group (n 	 8 per group) for one
of two independent experiments showing comparable results. *, P 

0.05 compared to saline, MenC-CRM197, and other groups. (b) MenC-
PS-specific IgG1 and IgG2a antibody levels 2 weeks after the second
immunization with MenC-CRM197. The results are presented as
mean  SD for each group (n 	 8 per group) for one of two inde-
pendent experiments showing comparable results.
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specific IgG2b levels were also higher in mice primed with
MenC-CRM197 plus BCG and reimmunized with MenC-
CRM197 than in mice primed with MenC-CRM197 only (P 

0.05), and IgG2a levels tended to be higher, although the
difference was not significant (P 	 0.06) (Fig. 3a).
Two weeks after the second immunization with MenC-
CRM197, the affinity maturation of MenC-PS-specific IgG was
detected only when neonatal mice were primed with MenC-
CRM197 plus BCG (Fig. 3b). Accordingly, after the MenC-
CRM197 reimmunization, only mice primed with MenC-CRM197
plus BCG had SBA titers of 128 (Fig. 2b), which was used as a
surrogate for protective efficacy (5).
DISCUSSION
BCG vaccination has been shown to induce protective im-
munity against M. tuberculosis in mice, both when given s.c.
(26) and intravenously (i.n.) (14), and the BCG vaccine dose in
these models was comparable (106 and 105, respectively) to the
dose used to assess adjuvant activity in our experiments. Pro-
tection against M. tuberculosis is dependent largely on innate
immunity and Th1-mediated immunity, and an effect of BCG
on antibodies to M. tuberculosis or heterologous antigens was
not reported (26). In prime-boost protocols for tuberculosis
vaccines, BCG has a dual function, as it primes for T-cell
responses to antigens shared by BCG and M. tuberculosis and
acts as an adjuvant for heterologous M. tuberculosis antigens
not present in BCG (43). The cell wall skeleton of BCG in-
FIG. 2. Effect of BCG on MenC-PS-specific IgG response and pro-
tective capacity when administered with MenC-CRM197 to neonatal
mice. Mice received BCG at the same time as the priming with MenC-
CRM197 at 1 week of age. Sixteen days later the mice received a second
immunization with MenC-CRM197 without BCG. (a) MenC-PS-spe-
cific IgG levels 2 weeks after priming (light gray columns) and 2 weeks
after the second immunization with MenC-CRM197 (dark gray col-
umns). The results are presented as mean  SD for each group (n 	
8 per group) for one of three independent experiments showing com-
parable results. *, P 
 0.05 compared to saline and MenC-CRM197
groups. (b) SBA induced by priming neonatal mice with MenC-
CRM197 with or without BCG, 2 weeks after the second immunization
with MenC-CRM197. Immunizations are indicated at bottom. SBA was
measured in pooled sera (equal volumes from each mouse within
group; n	 8 per group). SBA detection limit is 16 and is indicated with
a dotted line. Samples with undetectable SBA are arbitrarily assigned
an SBA titer of 8, corresponding to half the detection limit.
FIG. 3. The effect of BCG on IgG subclasses and avidity of MenC-
PS-specific antibodies. (a) IgG subclasses of MenC-PS-specific anti-
bodies 2 weeks after the second immunization with MenC-CRM197.
Mice received BCG at the same time as the priming with MenC-
CRM197 at 1 week of age. Sixteen days later the mice received a second
immunization with MenC-CRM197 without BCG. Immunizations are
indicated at bottom. IgG subclass levels (mean  SD) are presented
for each group (n 	 8 per group) for one of three independent
experiments showing comparable results. *, P 
 0.05 compared to
MenC-CRM197 group. (b) AI of MenC-PS-specific IgG 2 weeks after
the second immunization with MenC-CRM197. Immunizations are in-
dicated at bottom. AIs (expressed as M KSCN) are shown for individ-
ual mice, and a line indicates the mean for each group. Results are
presented for one of three independent experiments showing compa-
rable results. The AI detection limit was 0.117 (0.117 M KSCN).
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duces the maturation of dendritic cells (DC) through the in-
volvement of Toll-like receptor 2 (TLR-2) and TLR-4 (56).
The minimal structural unit of the peptidoglycan cell wall,
muramyl dipeptide (MDP), is responsible for the TLR-2- and
TLR-4-dependent DC maturation through the MyD88-depen-
dent pathway (57). This adjuvant effect of MDP has been used
successfully with hepatitis B virus surface antigen (HBsAg),
enhancing the immune responses specific for the antigen (23).
Adjuvants and BCG that stimulate dendritic cells to produce
interleukin-12 (IL-12) (27), which is limited in neonates (18),
may lead to stimulation of IL-21-producing follicular T-helper
cells (Tfh) (49), the key helper cells for B cells responding to
T-cell-dependent (TD) antigens, which would lead to an in-
crease in all IgG subclasses (reviewed in reference 37).
We assessed whether BCG was able to act as a adjuvant for
MenC-CRM197 by analyzing its effects on MenC-PS-specific
IgG levels and subclasses, avidity, and SBA. SBA has long been
the accepted correlate of protection when evaluating the pro-
tective efficacy of different meningococcal vaccines in humans
(17), and since humans are the only natural reservoir of
meningococci, SBA is also used in murine models to determine
the efficacy of vaccinations. The results demonstrate that BCG
has a significant adjuvant effect when given concomitantly with
MenC-CRM197, but no effect if administered a day or week
before. The adjuvant effect of BCG during the priming of
neonatal mice with MenC-CRM197 is still significant after two
reimmunizations with MenC-CRM197. The lack of adjuvant
effect in mice pretreated with BCG a day or a week before
MenC-CRM197 might be due to the activation of dendritic cells
by BCG, causing their migration to the lymph nodes and re-
sulting in a suboptimal response at the time of the MenC-
CRM197 immunization. C57BL/6 mice are most often used in
studies of immune responses to BCG or Mycobacterium tuber-
culosis, as they are inbred and susceptible to both bacteria (8),
whereas higher challenge doses are needed for outbred white
mice (12). Thus, the limited adjuvant effects of BCG on the
response to MenC-CRM197 could be the interplay between the
BCG dose used and the natural BCG resistance of NMRI
mice, leading to suboptimal stimulation of the immune system.
Dendritic cells are a reservoir for BCG and IL-12 production
by splenic dendritic cells, and induction of primary T-cell re-
sponses occurs only in the early phase of BCG infection (27),
which is in agreement with our results on the need for con-
comitant administration of BCG to have significant adjuvant
effect.
The second immunization was given 16 days after the prim-
ing, since it has been demonstrated that germinal center for-
mation peaks at day 14 in mice primed with tetanus toxoid as
neonates and at day 10 in mice primed as adults (40). Further-
more, the immunological maturation of 3-week-old mice cor-
responds to that of human infants (47, 48, 51). At 3 weeks of
age, before the second immunization, the mice primed as ne-
onates with MenC-CRM197 plus BCG already had enhanced
MenC-PS-specific IgG, indicating that the neonatal priming
was more efficient than that in the mice that did not receive
BCG during the priming. The second immunization in mice
primed as neonates with MenC-CRM197 plus BCG induced a
rapid increase in MenC-PS-specific IgG, indicating efficient
generation of memory by the neonatal priming compared to
that in the mice that did not receive BCG or saline. Impor-
tantly, BCG enhanced not only MenC-PS-specific IgG anti-
body levels in the mice, but also affinity maturation and func-
tional activity of the antibodies, reflected in an 8-fold increase
in SBA titers, to levels similar to those previously shown after
two immunizations with MenC-CRM197 together with the ad-
juvant LT-K63 or CpG (7). In mice primed as neonates with
MenC-CRM197 plus BCG concomitantly and boosted with
MenC-CRM197, SBA titers of 128 and 256 were obtained.
BCG also increased the avidity of the IgG antibodies and
altered the IgG subclass distribution, enhancing IgG2b and
IgG2a to a lesser extent, which were not induced by MenC-
CRM197 alone, in addition to enhancing IgG1 antibody levels
significantly. The BCG-induced enhancement of IgG1 and
IgG2b MenC-PS-specific antibodies suggests that BCG may
induce IL-12 production by dendritic cells to stimulate Tfh,
which are key inducers of the clonal expansion of B cells,
antibody isotype switching, plasma cell differentiation, and the
induction of germinal centers (reviewed in reference 37) pos-
sibly through enhanced production of IL-21, a fundamental
cytokine for Tfh generation (62) and the switching of naive
human B cells to IgG subclasses and IgA (2). IgG2a and IgG2b
are the most effective complement-fixing isotypes (58), which
may together with higher avidity contribute to increased SBA.
SBA titers of 4 are considered protective in humans, but baby
rabbit complement as used in this study gives a higher SBA
than human complement (66), since neither rabbit nor murine
factor H binds to the meningococcal surface (19). An SBA titer
of 128 is considered protective, since baby rabbit comple-
ment was used in the killing assay (5). The increase in avidity
and SBA and change in the distribution of the IgG subclasses
indicate that the adjuvant effect of BCG is mediated, at least in
part, through increased T-cell help which has been modulated
from a predominantly Th2-biased to a more mixed Th1/Th2
response.
Studies of human infants have shown that BCG adminis-
tered at birth enhances the IFN- responses of CD4 cells to
unrelated vaccines and increases antibody responses to hepa-
titis B virus surface antigen (HBsAg) (hepatitis B vaccine) and
oral polio vaccine serotype 1 (OPV-1) even when given 2
months after BCG priming (39).
The discrepancy between these results reported for humans
and the results from our murine study may be related to the
different natures of the vaccines (protein versus polysaccha-
ride-protein conjugate vaccines). Furthermore, in mice the ap-
pearance of B cells is delayed compared to that of T cells, the
splenic architecture appears at day 6, and germinal centers
appear 3 to 4 weeks after birth, whereas fetal thymocytes can
respond to mitogens already at day 17 of gestation (22). In
contrast, humans have functional B and T cells at birth. For
example, neonates primed with an acellular pertussis vaccine at
birth responded to a booster at 2 months of age with acceler-
ated immune responses to all pertussis antigens (29), and ne-
onates immunized with a 7-valent pneumococcal conjugate
were able to prime antigen-specific T-cell responses (59). On
the other hand, marginal zone B cells, which respond to T-cell-
independent antigens, like polysaccharides, do not appear until
after 2 years of age (65). We have previously shown that neo-
natal responses to the polysaccharide moiety of a pneumococ-
cal conjugate vaccine are more limited than responses to its
protein part, in antibody levels and the generation of memory
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B cells and antibody-secreting cells in spleen and bone marrow,
but can still be overcome by safe and effective adjuvants (4, 24)
(S. P. Bjarnarson, B. C. Adarna, H. Benonisson, G. Del Giu-
dice, and I. Jonsdottir, submitted for publication). Thus, stron-
ger B-cell-stimulating adjuvants may be needed to sufficiently
enhance the humoral response to conjugate vaccines.
Taken together, the results of this study show that BCG has
adjuvant effects on the priming of neonatal mice, if given
concomitantly with MenC-CRM197, which are comparable to
those of effective adjuvants like CpG and LT-K63. Thus, vac-
cination with polysaccharide-protein conjugates against menin-
gococcus and other encapsulated bacteria may benefit from
concomitant administration with BCG in the neonatal period
to accelerate and enhance production of protective antibodies.
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